Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

46.4K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
46.4K
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

223
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
223
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

859
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
859

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploring Phosphatidylethanol Cutoffs for Self-Reported Unhealthy Alcohol Use: An International Multi-Site Analysis.

Alcohol, clinical & experimental research·2026
Same author

Non-Hispanic Black Persons With HIV Have a Lower Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease and Clinically Significant Fibrosis Compared to Non-Hispanic White and Hispanic Individuals.

Open forum infectious diseases·2026
Same author

Utilizing Telemedicine to Engage Rural Patients With Substance Use Disorders in Low Barrier Hepatitis C Treatment.

Journal of viral hepatitis·2026
Same author

Single-cell hepatitis B sequencing reveals distinct viral infection events consistent with superinfection.

The Journal of infectious diseases·2026
Same author

Health economic outcomes of a minimal monitoring approach to providing HCV therapy.

Hepatology communications·2025
Same author

Impact of a minimal monitoring HCV treatment approach on Health-Related Quality of Life.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation·2025

Related Experiment Video

Updated: Aug 8, 2025

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

6.9K

Hepatitis D virus infection: Progress on the path toward disease control and cure.

Mark S Sulkowski1

  • 1Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Journal of Viral Hepatitis
|March 1, 2023
PubMed
Summary

Hepatitis D virus (HDV) significantly worsens liver disease in Hepatitis B virus (HBV) patients. New treatments targeting HBsAg loss are emerging, alongside regulatory acceptance of surrogate endpoints for HDV drug development.

More Related Videos

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

13.3K
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

9.8K

Related Experiment Videos

Last Updated: Aug 8, 2025

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

6.9K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

13.3K
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

9.8K

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Hepatitis D virus (HDV) infection exacerbates liver disease severity and mortality in individuals with Hepatitis B virus (HBV) infection.
  • Current understanding of HDV epidemiology, pathogenesis, and natural history reveals significant knowledge gaps.

Purpose of the Study:

  • To review current knowledge and identify unanswered questions regarding HDV infection.
  • To explore novel therapeutic strategies for co-infected HBV/HDV patients.
  • To discuss the implications of regulatory acceptance of surrogate endpoints for HDV drug development.

Main Methods:

  • Literature review of epidemiology, pathogenesis, and natural history of HDV.
  • Analysis of current treatment limitations and proposed novel therapeutic targets.
  • Discussion of regulatory advancements in drug development for HDV.

Main Results:

  • Interferon alfa shows suboptimal response rates for HDV treatment, with limited sustained virologic response.
  • Novel strategies focus on reducing or eliminating hepatitis B surface antigen (HBsAg).
  • Regulatory bodies now accept viral and biochemical surrogates, facilitating clinical development.

Conclusions:

  • HDV poses a significant threat to liver health in HBV-infected individuals.
  • Development of effective HDV therapies is crucial, with a focus on HBsAg clearance.
  • Regulatory flexibility is accelerating the pipeline for new HDV treatments.